Herpes Infection Treatment Market (By Product: Therapeutics, Vaccine; By Type: HSV; By Drug; By Route of Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030

The growth of the herpes infection treatment market is attributed to an increasing prevalence of herpes infection globally and growing awareness about the disease. For instance, according to WHO, in 2020, nearly 50 million of the population were suffering from genital herpes caused by type 1 or type 2 of the herpes simplex virus HSV, and several billion people have oral infections. The asymptomatic nature of the condition, escalates its transmission rate, thereby creating a market opportunity for treatments.

The therapeutics segment includes drugs of which valacyclovir drug dominated the market as it is cost-effective, readily available, and effective in blocking the virus from reproducing in the body, thereby aiding to control the symptoms of an outbreak. Moreover, valacyclovir is most widely used for cold sores attributable to its higher absorption rate. There are efforts and investments that have been done to provide vaccination for the disease condition which is expected to boost the growth of the vaccine segment. Key players operating in the herpes infection marketplace are focusing on developing vaccines, for instance, in July 2021, GlaxoSmithKline plc announced the U.S. FDA approval of Shingrix for the prevention of shingles caused by herpes zoster.

North America dominated the overall market in 2021 which can be attributed to escalating healthcare expenditure, higher consumption of branded herpes infection treatment drugs, increasing launch of generics, and favorable reimbursement policies. Increasing disease prevalence, and growing geriatric and immunocompromised population in the region are increasing awareness among the population which further propels the growth of the market. For instance, in 2021, according to CDC, HSV was one of the most prevalent sexually transmitted infections in the United States. Furthermore, to meet the high demand for effective treatment options, major key players are focusing on expanding their product portfolios. For instance, in 2022, Moderna, Inc. expanded its mRNA pipeline with three new development programs to reduce the rates of shingles. 

Major companies operating in the market include Teva Pharmaceutical Industries Ltd.; Abbott; GlaxoSmithKline plc; Cipla Inc.; Eli Lilly and Company; Merck & Co., Inc.; Novartis AG; F. Hoffmann-La Roche Ltd. These players are focusing on mergers and acquisition to maintain its presence over the market. For instance, in January 2022, Pfizer and BioNTech signed a collaboration agreement to develop first mRNA-based shingles infection vaccine. This agreement aims to accelerate the development of an improved vaccine for shingles infection.

Market Segmentation

  • By Product
    • Therapeutics
    • Vaccine
  • By Type
    • Herpes Simplex 
      • Herpes Simplex 1
      • Herpes Simplex 2
    • Herpes Zoster
  • By Drug
    • Acyclovir
    • Valacyclovir
    • Famciclovir
    • Others
  • By Route of Administration
    • Oral
    • Topical
    • Injection
  • By Distribution Channel
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Herpes Infection Treatment Market 

5.1. COVID-19 Landscape: Herpes Infection Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Herpes Infection Treatment Market, By Product

8.1. Herpes Infection Treatment Market, by Product, 2022-2030

8.1.1. Therapeutics

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Vaccine

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Herpes Infection Treatment Market, By Type

9.1. Herpes Infection Treatment Market, by Type, 2022-2030

9.1.1. Herpes Simplex

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Herpes Zoster

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Herpes Infection Treatment Market, By Drug 

10.1. Herpes Infection Treatment Market, by Drug, 2022-2030

10.1.1. Acyclovir

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Valacyclovir

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Famciclovir

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Herpes Infection Treatment Market, By Route of Administration

11.1. Herpes Infection Treatment Market, by Route of Administration, 2022-2030

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Topical

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Injection

11.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Herpes Infection Treatment Market, By Distribution Channel

12.1. Herpes Infection Treatment Market, by Distribution Channel, 2022-2030

12.1.1. Hospital Pharmacy

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Retail Pharmacy

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Online Pharmacy

12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Herpes Infection Treatment Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.2. Market Revenue and Forecast, by Type (2017-2030)

13.1.3. Market Revenue and Forecast, by Drug (2017-2030)

13.1.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.7. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Type (2017-2030)

13.1.8.3. Market Revenue and Forecast, by Drug (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.1.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.4. Market Revenue and Forecast, by Route of Administration (2017-2030) 

13.2.5. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.7. Market Revenue and Forecast, by Route of Administration (2017-2030) 

13.2.8. Market Revenue and Forecast, by Distribution Channel (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.10. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.11. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.13. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Type (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Drug (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.2.15. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Type (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Drug (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.3.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.9. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.10.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Type (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Drug (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.4.11.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.2. Market Revenue and Forecast, by Type (2017-2030)

13.5.3. Market Revenue and Forecast, by Drug (2017-2030)

13.5.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Type (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Drug (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.7. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Type (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Drug (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Route of Administration (2017-2030)

13.5.8.5. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 14. Company Profiles

14.1. Teva Pharmaceutical Industries Ltd.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Abbott

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. GlaxoSmithKline plc

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Cipla Inc.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Eli Lilly and Company

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck & Co., Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Novartis AG

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. F. Hoffmann-La Roche Ltd

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert